[en] 18 FDG- PET is an imagining technique based on metabolic criteria rather than morphological criteria. (18) FDG- PET can demonstrate accelerated glycosis in cancer tissue related to increased transporter and glycolytic enzyme activity. Whole body PET is currently under validation in a growing number of indications during diagnostic and therapeutic assessment phases of cancer treatment. In the field of pulmonary oncology, (18) FDG- PET has already demonstrated its performance capacity to: 1) discriminate the malignant nature of a solitary pulmonary nodule, 2) improve sensitivity over CT for mediastinal assessment in small-cell lung cancer, 3) acquire whole body imaging to search for distant metastasis in patients with small-cell lung cancer; PET is particularly useful for evaluation of an adrenal mass, 4) complement CT imaging to better dissociate tumor residue or recurrence from post-therapeutic sequelae in small-cell lung cancer. Information provided by (18) FDG- PET is thus clinically relevant as it allows better dissociation of a benign process from a malignant process and better precision of small-cell lung cancer extension without necessitating systematic invasive exploration.
Disciplines :
Oncology Cardiovascular & respiratory systems
Author, co-author :
Bury, Thierry ; Université de Liège - ULiège > Département des sciences de la motricité > Physiologie humaine et physiologie de l'effort physique
Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Language :
French
Title :
Intérêt de la tomographie à émission de positons dans la prise en charge du cancer broncho-pulmonaire
Alternative titles :
[en] Contribution of Positron Emission Tomography for the Management of Lung Cancer
Quint L.E., Francis I.R., Wahl R.L., Gross B.H., Glazer G.M. : Preoperative staging of non-small cell carcinoma of the lung : imaging methods. Am. J. Roentgenol., 1995, 164, 1349-59.
Kazerooni E.A., Lim F.T., Mikhail A., Martinez F J. : Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology, 1996, 198, 371-5.
Al-Sugair A., Coleman E. : Applications of PET in lung cancer. Sem. Nucl. Med., 1998, 28, 303-19.
Warburg O. : The metabolism of tumors In Smith RR Inc, New York 1931 : p. 129-139
Midthun D., Swensen S., Pett J. : Clinical strategies for solitary pulmonary nodules. Ann. Rev. Med., 1992, 93, 195-208.
Bury T., Dowlati A., Paulus P., Corhay J.L., Benoit T., Kayembe J.M., Limet R., Rigo P., Radermecker M. : Evalution of the solitary pulmonary nodule by PET imaging. Eur. Resp. J., 1996, 9, 410-4.
Rigo P., Paulus P., Kaschten B.J., Hustinx R., Bury T., Jerusalem G., Benoit T., Foidart J. : Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose. Eur. J. Nucl. Med., 1996, 23, 1641-74.
Crisci R., Pavone P., Passariello R., Coloni G. : Bilan d'extension ganglionnaire médiastinal du cancer bronchique. Rev. Mal. Resp., 1991, 8, 205-8.
Shields T. : The significance of ipsilateral mediastinal lymph node metastatic (N2 disease) in non-small cell carcinoma of the lung. Thorac. Cardiovasc. Surg., 1990, 99, 48-53.
Bury T., Paulus P., Dowlati A., Corhay J.L., Weber T., Ghaye B., Schoffers J., Limet R., Albert A., Rigo P., Radermecker M. : Staging of the mediastinum : value of positron emission tomography imaging in non-small cell lung cancer. Eur. Respir. J., 1996, 9, 2560-4.
Vansteenkiste J.F., Stroobandt S.G., Dupont P.J., De Leyn P.R., De Wever W.F., Verbeken E.K., Nuyts J.L., Maes F.P., Bogaert J.G. and the Leuven Lung Cancer Group : FDG-PET scan in potentially operable non-small cell lung cancer : do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases ? Eur. J. Nucl. Med., 1998, 25, 1495-501.
Bury T., Dowlati A., Paulus P., Corhay J.L., Hustinx R., Ghaye B., Radermecker P., Rigo P. : Wholde-body 18FDG-PET in the staging of non small cell lung cancer. Eur. Respir. J., 1997, 10, 2529-34.
Lewis P., Griffin S., Marsden P., Gee T., Nunan T., Malsey M., Dussek J. : Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet, 1994, 344, 1265-6.
Valk P.E., Pounds T.R., Hopkins D.M., Haseman M.K., Hofer G.A., Greeiss H.B., Myers R.W., Lutrin C.L. : Staging lung cancer by PET imaging. Ann. Thorac. Surg., 1995, 60, 1573-82.
Patz E.F., Lowe V.J., Hoffman J.M., Paine S.S., Harris L.K., Goodman P.C. : Persistent or recurrent bronchogenic carcinoma : detection with PET and 2-(F-18)-2-deoxy-D-glucose Radiology, 1994, 191, 379-82.
Inoue T., Kim E.E., Komaki R., Wong F., Bassa P., Wong W., Yang D., Endo K., Podoloff D. : Detecting recurrent of residual lung cancer with FDG-PET. J. Nucl. Med., 1995, 37, 788-93.
